Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RRM1 | P23921 | 2/20 | 0.33 |
| ▸ | RRM2 | P31350 | 2/20 | 0.33 |
| ▸ | RRM2B | Q7LG56 | 2/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.33 |
| ▸ | CTSG | P08311 | 1/20 | 0.33 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.33 |
| ▸ | CMA1 | P23946 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 5/20 | 0.31 |
| ▸ | MMP3 | P08254 | 5/20 | 0.31 |
| ▸ | MMP1 | P03956 | 3/20 | 0.31 |
| ▸ | MMP7 | P09237 | 1/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27439171 | 0.80 | CTSK (0.43) | PRSS1CTSGCTRB1CMA1CTSK | |
| SCHEMBL13686139 | 0.78 | ADAM17 (0.31) | — | |
| SCHEMBL14376297 | 0.77 | KDM4E (0.35) | RRM1RRM2RRM2BPRSS1CTSG | |
| SCHEMBL12086289 | 0.77 | KDM4E (0.35) | RRM1RRM2RRM2BPRSS1CTSG | |
| SCHEMBL13686207 | 0.76 | ALDH1A1 (0.32) | — | |
| SCHEMBL5207103 | 0.76 | TSHR (0.33) | RRM1RRM2RRM2BPRSS1CTSG | |
| SCHEMBL10066634 | 0.76 | CYP2C9 (0.45) | RRM1RRM2RRM2BPRSS1CTSG | |
| SCHEMBL25583790 | 0.76 | CYP2C9 (0.45) | RRM1RRM2RRM2BPRSS1CTSG | |
| SCHEMBL12404657 | 0.76 | CNR2 (0.39) | RRM1RRM2RRM2BPRSS1CTSG | |
| SCHEMBL5204828 | 0.75 | PRSS1 (0.31) | PRSS1CTSGCTRB1CMA1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090082369-A1 | Pyrrolo[2,3d]pyrimidine compositions and their use | OSI PHARMACEUTICALS, INC. | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082369-A1 | Pyrrolo[2,3d]pyrimidine compositions and their use | ADORA3, ADORA2A, ADORA1 | RRM1 181/4885RRM2 72/4885RRM2B 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.